OXB recognised as ‘Most Innovative CDMO (Cell & Gene)’ at 2026 CDMO Leadership Awards

Oxford, UK - 27 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised with the 'Most Innovative CDMO (Cell and Gene Therapy)' award at the CDMO Leadership Awards in New York City.